Cognition Disorders Clinical Trial
Official title:
Cognitive Effects of Body Temperature During Hypothermic Circulatory Arrest
In this study the investigator will randomize 273 subjects to deep (<20°C), low (20.1°C-24°C), or moderate (24.1°C-28°C) hypothermia during aortic arch surgery with circulatory arrest. The primary purpose of this study is to determine the effect of deep vs low vs moderate hypothermia on neurocognitive function, brain functional connectivity, and leukocyte SUMOylation patterns after surgical circulatory arrest in participants.
Purpose of the Study: Determine the effect of deep vs low vs moderate hypothermia on neurocognitive function, brain functional connectivity, and leukocyte SUMOylation patterns after surgical circulatory arrest. Hypothesis: Deep hypothermia is superior to moderate hypothermia in reducing postoperative cognitive decline and preserving brain functional connectivity and that low hypothermia is non-inferior to deep hypothermia. Design and Procedures: 273 informed and consenting patients who are scheduled for elective proximal aortic reconstructive surgery (ascending aorta + aortic valve or root) with concomitant proximal hemi- or total arch replacement via median sternotomy will be randomized to deep (<20°C), low (20.1°C-24°C), or moderate (24.1°C-28°C) hypothermia during circulatory arrest. Cognitive testing using a standard battery will occur preoperatively (baseline), at 4 weeks, and at 1 year after surgery. Neuroimaging procedures before surgery, and at 4 weeks and 1 year after surgery will consist of high-resolution anatomic, resting-state fMRI (rs-fMRI) and magnetic resonance spectroscopy (MRS) sequences. To characterize leukocyte activation, whole blood will be drawn at 5 time points: at baseline (prior to surgery), before circulatory arrest, 10 minutes after reperfusion, 10 minutes after CPB, and 4 hours after CPB. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02488720 -
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
|
||
| Recruiting |
NCT03544801 -
Renji Cerebral Small Vessel Disease Corhort Study
|
||
| Recruiting |
NCT02813434 -
Cerebral Amyloid Imaging Using Florbetapir (AV-45)
|
Phase 3 | |
| Completed |
NCT00400790 -
Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane
|
N/A | |
| Completed |
NCT00052091 -
Therapy for Depressed Elders With Thought Problems
|
Phase 3 | |
| Completed |
NCT00021866 -
Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy
|
N/A | |
| Completed |
NCT00267163 -
Brain Imaging and Mental Disorders of Aging Intervention
|
Phase 4 | |
| Not yet recruiting |
NCT04079075 -
Multiple Interventions to Prevent Cognitive Decline
|
N/A | |
| Terminated |
NCT03696082 -
A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines
|
N/A | |
| Completed |
NCT02918539 -
Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
|
||
| Active, not recruiting |
NCT01708837 -
Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction
|
Phase 4 | |
| Completed |
NCT01290939 -
Bevacizumab and Lomustine for Recurrent GBM
|
Phase 3 | |
| Terminated |
NCT00548327 -
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype
|
Phase 2 | |
| Unknown status |
NCT00256425 -
Cognitive Rehabilitation of Glioma Patients
|
Phase 3 | |
| Recruiting |
NCT03926351 -
High Dose Omega 3 in People at Risk for Dementia
|
Phase 2 | |
| Completed |
NCT02118571 -
Schizophrenia Cognition Scale Development
|
N/A | |
| Completed |
NCT01481961 -
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease
|
N/A | |
| Completed |
NCT00788918 -
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)
|
N/A | |
| Completed |
NCT00564902 -
The Zeaxanthin and Visual Function Study
|
N/A | |
| Completed |
NCT00529581 -
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
|
Phase 2 |